NewAmsterdam’s bid to revive Amgen cardio drug heads to Nasdaq in Frazier SPAC deal

Five years after Amgen buried its CETP cholesterol drug, a Dutch biotech with hundreds of millions in funding is headed to Wall Street to continue testing the therapy in Phase III trials. A month after spreading the news about securing $123 million upfront in an overall €1 billion deal, NewAmsterdam…

Click to view original post